What is HC Wainwright’s Estimate for Longeveron Q1 Earnings?

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at HC Wainwright lifted their Q1 2025 earnings estimates for shares of Longeveron in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their prior estimate of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.31) EPS.

Several other equities analysts have also weighed in on LGVN. Roth Mkm initiated coverage on Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 target price on the stock. Roth Capital raised Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th.

Longeveron Stock Up 4.9 %

LGVN stock opened at $1.51 on Thursday. Longeveron has a twelve month low of $0.77 and a twelve month high of $6.40. The business’s fifty day moving average is $1.64 and its 200-day moving average is $1.89. The company has a market cap of $22.40 million, a P/E ratio of -0.24 and a beta of 0.37.

Institutional Trading of Longeveron

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares during the period. Virtu Financial LLC bought a new position in shares of Longeveron during the 4th quarter valued at about $53,000. Jane Street Group LLC bought a new position in shares of Longeveron during the 4th quarter valued at about $35,000. Northern Trust Corp acquired a new position in shares of Longeveron in the 4th quarter valued at approximately $31,000. Finally, State Street Corp bought a new stake in Longeveron during the 3rd quarter worth approximately $29,000. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.